Founded 1989


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 469
Average round size
The average size of a deal this fund participated in
Portfolio companies 317
Rounds per year 14.66
Lead investments 123
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 166
Key employees 15
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Therapeutics

In 1989 was created OrbiMed, which is appeared as VC. The venture was found in North America in United States. The leading representative office of defined VC is situated in the New York.

Besides them, we counted 15 critical employees of this fund in our database.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the OrbiMed, startups are often financed by New Enterprise Associates, Kearny Venture Partners, Sequoia Capital. The meaningful sponsors for the fund in investment in the same round are Deerfield, Alta Partners, Topspin Partners. In the next rounds fund is usually obtained by Versant Ventures, Venrock, OUP (Osage University Partners).

Among the most popular portfolio startups of the fund, we may highlight Loxo Oncology, Receptos, Avanir Pharmaceuticals. Among the most popular fund investment industries, there are Biotechnology, Clinical Trials. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

Speaking about the real fund results, this VC is 22 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars. The typical startup value when the investment from OrbiMed is 100-500 millions dollars. Opposing the other organizations, this OrbiMed works on 6 percentage points more the average amount of lead investments. The top amount of exits for fund were in 2015. The fund is generally included in 13-24 deals every year.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of OrbiMed:
Typical Co-investors
OrbiMed is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after OrbiMed:

Funds with similar focus

Funds from United States, New York
Funds with similar focus located in United States, New York:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Disc Medicine

Health Care
$90M02 Sep 2021 United States, Cambridge


Health Care
Health Diagnostics
$60M26 Aug 2021 United States, " United States"}

Vigil Neuroscience

$90M18 Aug 2021 United States, Cambridge

Carrot Fertility

Employee Benefits
Human Resources
$75M17 Aug 2021 United States, San Francisco


Life Science
$157M11 Aug 2021 United States, Seattle


Life Science
$50M04 Aug 2021 United States, San Diego

Pulnovo Medical

Medical Device
$15M03 Aug 2021 China, Wuxi

Owlet Baby Care

Big Data
Consumer Electronics
Health Care
$130M16 Jul 2021 United States, Lehi


Artificial Intelligence
Machine Learning
$53M14 Jul 2021 United States, Los Angeles
Garuda Therapeutics Raises $72M in Series A Financing
– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies. – Series A funding of $72m brings company valuation to more than $1b. – The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others. Read more
Amolyt Pharma Raises $80M in Series B Financing
– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases. – The company closed an $80m Series B round. – The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation. – The company plans to use the proceeds from th... Read more


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent OrbiMed?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: